[junkie-button url=”http://infomeddnews.com/” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]
Second Sight Medical Products, Inc. (NASDAQ:EYES) a developer, manufacturer and marketer of implantable visual prosthetics that provide useful vision to blind patients, today announced the appointment of Frank Vandeputte as Vice President and General Manager, EMEA and Asia Pacific, where he will lead all commercial activities for the Company outside of North America.
The company reports Mr. Vandeputte is an international sales and marketing executive with extensive commercial experience in high-tech medical devices, including senior positions with TriVascular, Inc., Aptus Endosystems, EBR Systems, Inc., Oxford Immuniotech, Sorin Group and Guidant. He also has a track record of launching innovative technologies with a focus on driving adoption, and managing and building new businesses throughout the European Union. He will report directly to Mr. Will McGuire, Second Sight’s President and Chief Executive Officer.
“Frank joins us with more than 30 years of sales and marketing experience in medical devices. His leadership and commercialization experience, coupled with our strong team in Europe, will position us for continued success outside of the U.S. and Canada,” said Will McGuire.
In addition, Gregoire Cosendai has been appointed as Vice President, Clinical Affairs. Dr. Cosendai will direct all clinical activities including feasibility and pivotal trials for the Orion™ Cortical Visual Prosthesis System (Orion), as well as clinical trials designed to expand the population of patients treatable by the Argus® II Retinal Prosthesis System to include retinitis pigmentosa (RP) patients with better vision. Dr. Cosendai was formerly Vice President of European Operations for the Company. He will continue to report to Mr. McGuire.
McGuire also commented on Dr. Cosendai’s new role, “I’m also very pleased that Greg has assumed a new position leading our clinical affairs team. His first priority is the initiation of the Orion feasibility trial followed by the planning and execution of a pivotal trial. Orion is an exciting technology that can potentially restore useful vision to millions of patients who today have no option,” concluded McGuire.